When multiple myeloma relapses
RESPOND with a treatment with a low incidence of peripheral neuropathy
Peripheral neuropathy (grade ≥2)1
- Patients were 5× less likely to have peripheral neuropathy with Kd than with Vd1
Refer to Summary of Product Characteristics and Prescribing Information for comprehensive safety information
Frequency of AEs may vary between studies. Refer to SmPC for selected
AEs reported in clinical studies.2
*In the intention-to-treat population: Kd (n=464) and Vd (n=465).
Please read the SmPC for full comprehensive safety information
- Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.
- Kyprolis® (carfilzomib) Summary of Product Characteristics; 2016.